---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-015662"
form_type: "8-K"
ticker: "MAIA"
cik: "0001878313"
company_name: "MAIA Biotechnology, Inc."
filed_at: "2026-04-08T23:59:59+00:00"
generated_at: "2026-05-15T06:55:47.535147+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# MAIA Biotechnology: $33M raise fully funds pivotal Phase 3 trial for ateganosine in NSCLC

## Summary
- Net proceeds from $33M March 2026 common stock offering expected to fully fund pivotal Phase 3 trial (THIO-104) for ateganosine in third-line NSCLC.
- FDA granted Fast Track designation for ateganosine, a dual mechanism telomere-targeting agent, for third-line NSCLC treatment.
- Statistical assessments based on Phase 2 data point to high probability of technical success in Phase 3 full approval trial.
- Interim Phase 3 data expected next year; may support FDA discussion for early full commercial approval in third-line NSCLC.

## SEC filing metadata
- accession: 0001493152-26-015662
- form_type: 8-K
- ticker: MAIA
- cik: 0001878313
- company_name: MAIA Biotechnology, Inc.
- filed_at: 2026-04-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1878313/000149315226015662/0001493152-26-015662-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1878313/000149315226015662/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-015662
- JSON: https://secwatch.observer/filing/0001493152-26-015662.json
- Plain text: https://secwatch.observer/filing/0001493152-26-015662.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.